Actively Recruiting
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Led by NewAmsterdam Pharma · Updated on 2026-04-09
69
Participants Needed
1
Research Sites
113 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16
CONDITIONS
Official Title
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Lipoprotein (a) (Lp[a]) \u226550 mg/dL for cohort 1 or Lp(a) between 20 and less than 50 mg/dL for cohort 2
- LDL cholesterol above 70 mg/dL
- Triglycerides less than 400 mg/dL
You will not qualify if you...
- HbA1c 10 or higher or fasting plasma glucose 270 mg/dL or higher
- Cardiovascular events within 3 months before screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UPenn
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
A
Ashley Walker
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here